US Food and Drug Administration (USFDA) has completed inspection at Natco Pharma’s Active Pharmaceutical Ingredient (API) facility in Chennai in the state of Tamil Nadu. The inspection was conducted from July 8 to July 12, 2019. The regulatory audit resulted in zero observations.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.